Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
Scienture Holdings, Inc. amended Amended and Restated Agreement and Plan of Merger with Superlatus, Inc. valued at Company Equity Value adjusted to 12,500,000; Merger Consideration adjusted to 1,712,328 shares of co (effective 2024-01-08).
- Action
- amendment
- Agreement
- merger
- Counterparty
- Superlatus, Inc.
- Value
- Company Equity Value adjusted to 12,500,000; Merger Consideration adjusted to 1,712,328 shares of co
- Effective
- 2024-01-08
Exact text from the filing
As previously reported on a Current Report on Form 8-K filed on July 31, 2023 TRxADE HEALTH, Inc., a Delaware corporation (the “Company”), completed its acquisition of Superlatus, Inc., (“Superlatus”) and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”) in accordance with the terms and conditions of the Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which the Company acquired Superlatus by way of a merger of the Merger Sub with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the merger (“Merger”). Superlatus was not able to meet the post-closing condition of acquiring Prestige Farms, Inc. and on January 8, 2024, the Company entered into an amendment agreement to the Merger Agreement with Superlatus and Merger Sub (the “Amendment”).
View on SEC.gov